Prolocor

Prolocor is a private, pre-revenue diagnostics company pioneering a precision medicine approach to cardiovascular disease (CVD). Its core technology is a diagnostic test measuring platelet surface FcγRIIa expression, a biomarker implicated in amplifying platelet activation and thrombosis. The company is actively validating this biomarker through multiple observational clinical trials in areas like myocardial infarction, stroke, and cancer-associated thrombosis. If successful, Prolocor's test could address a significant unmet need for tools that personalize antiplatelet therapy and improve CVD outcomes.

Diagnostic test quantifying FcγRIIa receptor expression on the surface of platelets to assess individual risk for thrombotic events.

Prolocor's direct competitive landscape for a platelet FcγRIIa diagnostic appears sparse, positioning it as a first-mover in a novel niche. However, it competes indirectly with other risk-stratification approaches in cardiology, including genetic tests (e.g., for clopidogrel metabolism), other functional platelet assays, and clinical risk scores. Its ultimate success depends on proving superior or additive predictive value.